OptimumBank Holdings, Inc. Financial Performance for the Second Quarter of 2026

OptimumBank Holdings, Inc. (OPHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 OptimumBank Holdings, Inc. Financial Performance for the Second Quarter of 2026 Fort Lauderdale, FL, July 24, 2026 — OptimumBank Holdings, Inc. (NYSE American: OPHC) (the “Company”) is a financial holding company and owns 100% of OptimumB

Original reporting
Published Jul 24, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$OPHC
Bullish
medium confidence
Mentioned
$OPHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OPHCBullishMed
01

Why it matters

The filing discloses a full quarterly earnings snapshot plus balance-sheet growth, NIM movement, efficiency ratio, and credit performance, which can drive near-term valuation and positioning for OPHC.

02

Market read

Fresh quarterly earnings and operating metrics (net income, NIM, ROAA/ROAE, loans and deposits) provide actionable inputs for OPHC positioning ahead of the Aug 13 webcast.

03

What to watch

Credit loss reversal was positive, but the allowance is 0.91% of loans; traders may want to watch whether charge-offs rise as the portfolio expands, especially in CRE segments.

Relevance 7/10Novelty 7/10Timing: Filed today (pre-market) with Q2 results; webcast scheduled for Aug 13, 2026.

Background

This is an SEC 8-K (Item 2.02) with Exhibit 99.1 covering OptimumBank Holdings’ Q2 2026 financial performance and related operating highlights.

Company-level read

Ticker impact

$OPHCBullishMedium confidence
Context

OptimumBank Holdings reported Q2 2026 net income of $6.7M, with ROAA 2.04% and net interest margin rising to 4.57%.

Expected impact

Mildly positive bias for the next few sessions, assuming the market rewards NIM and deposit growth more than the expense/tax drag.

Evidence & confidence

The filing provides multiple fresh datapoints (income statement, NIM, ROAA/ROAE, loan/deposit growth, credit metrics) that can change trader expectations versus the prior quarter.

Market effects

Adds another datapoint on small-bank profitability drivers, especially net interest margin expansion and deposit growth sustainability.

Limited direct read-across beyond Florida/US community banking, but supports the broader small-cap bank earnings tape.

Low; this is a US small financial holding company with no stated global catalyst.

Counterpoint

Loan growth is strong, but noninterest expenses rose and income tax expense increased, which could limit how much of the NIM improvement flows through to sustainable earnings.

Key entities

  • OptimumBank Holdings, Inc.

    Financial holding company reporting Q2 2026 results, including net income, NIM, loan/deposit growth, and credit metrics.

  • OptimumBank

    Florida-chartered commercial bank wholly owned by OptimumBank Holdings, referenced as the operating entity behind the results.

  • Moishe Gubin

    Chairman and CEO who assumed CEO role effective May 1, 2026, per the filing.

  • Braden R. Smith

    Joined as President effective May 1, 2026, per the filing.

Related articles

$OPHCHigh

OptimumBank Holdings, Inc. Financial Performance for the Third Quarter of 2026

OptimumBank Holdings, Inc. (OPHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OptimumBank Holdings, Inc. Financial Performance for the Third Quarter of 2026 Fort Lauderdale, FL, November 12, 2026 — OptimumBank Holdings, Inc. (NYSE American: OPHC) (the “Company”) is a financial holding company and owns 100% of OptimumBank (the “Bank”), a Florid

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

HighAI 8/10

Merck KGaA Earnings Call Signals Stronger Growth Ahead

Merck KGaA (MKKGY) reported Q3 earnings with accelerated growth, raised full-year guidance, and announced strategic investments. Key highlights include 5.1% organic sales growth, EUR 1.66B operating cash flow, and plans to acquire Silence Therapeutics. Management emphasized growth in biomanufacturing, semiconductors, and rare diseases, while noting Mavenclad's declining sales and softer demand in consumer electronics.